NCT06254521 is a Phase 2 clinical trial of Tislelizumab combined with chemotherapy in Rectal Cancer, sponsored by First Affiliated Hospital of Guangxi Medical University.

Who is sponsoring NCT06254521?

NCT06254521 is sponsored by First Affiliated Hospital of Guangxi Medical University.

What drugs are being tested in NCT06254521?

Interventions in NCT06254521: Tislelizumab combined with chemotherapy.

What condition does NCT06254521 study?

NCT06254521 studies Rectal Cancer, Rectal Cancer Stage II, Rectal Cancer Stage III.

Is NCT06254521 still recruiting?

NCT06254521 is currently recruiting now. Last updated 12 February 2024.

Last reviewed 2024-02-12 · How we verify

NCT06254521

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effects of Neoadjuvant Tislelizumab Combined With Chemotherapy in Locally Advanced MSS Rectal Cancer

Recruiting now Phase 2 Last updated 12 February 2024

What this trial tests

Phase 2 trial testing Tislelizumab combined with chemotherapy in Rectal Cancer in 60 participants. Currently enrolling.

Timeline

22 February 2024

Primary endpoint
30 December 2024

30 December 2027

Quick facts

Lead sponsor	First Affiliated Hospital of Guangxi Medical University
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	60
Start date	22 February 2024
Primary completion	30 December 2024
Estimated completion	30 December 2027
Sites	1 location across China

Drugs / interventions tested

Tislelizumab combined with chemotherapy — full drug profile →

Conditions studied

Rectal Cancer — all drugs for Rectal Cancer →
Rectal Cancer Stage II — all drugs for Rectal Cancer Stage II →
Rectal Cancer Stage III — all drugs for Rectal Cancer Stage III →

Sponsor

First Affiliated Hospital of Guangxi Medical University

Who can join

18 and older, any sex, with Rectal Cancer or Rectal Cancer Stage II. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to elucidate the effects of neoadjuvant Tislelizumab combined with chemotherapy in locally advanced MSS rectal cancer.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Surgical management of suspected paraneoplastic myasthenia gravis in rectal cancer during neoadjuvant immunotherapy: a case report.
Xia Z, Chen H, Qiu M, Huang W, et al · · 2025 · PMID 40963855 · DOI 10.3389/fonc.2025.1503362

Verify or expand the search:

Other recruiting trials for Rectal Cancer

Currently open trials in the same condition.

NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
NCT07537998 — Antegrade Intestinal Fluid Reinfusion for Prevention of Low Anterior Resection Syndrome After Low Anterior Resection: a · Phase 2, PHASE3 · recruiting
NCT07501845 — Registry Maastro Applicator · recruiting
NCT07369531 — The Impact of Two-Stage Turnbull-Cutait Pull-Through Coloanal Anastomosis on Stoma-free Survival in Low Rectal Anal-pres · NA · recruiting
NCT07505472 — Efficacy and Safety Comparison of Short-course Radiotherapy Followed by CapeOX Chemotherapy Plus Toripalimab With or Wit · Phase 2, PHASE3 · recruiting

Other First Affiliated Hospital of Guangxi Medical University trials

Trials by the same sponsor.

NCT07459296 — Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC · Phase 3 · recruiting
NCT07342322 — A Prospective, Multicenter, Open-label, Single-arm Phase II Clinical Study Evaluating the Efficacy and Safety of Spatial · Phase 2 · not yet recruiting
NCT07338357 — Clinical Study of CLL-1 CAR-T in the Treatment of Children With R/R AML · EARLY_PHASE1 · not yet recruiting
NCT07132008 — Neoadjuvant CAPOX Plus Tislelizumab vs CAPOX in MSS High-Risk Locally Advanced Colon Cancer · Phase 3 · not yet recruiting
NCT07074444 — Treatment of Clonorchiasis in Guangxi With Albendazole, Tribendimidine, and Praziquantel · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06254521 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by First Affiliated Hospital of Guangxi Medical University
Last refreshed: 12 February 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06254521.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing